GD2 CAR-NKT cell therapy

3rd generation GD2-specific chimeric antigen receptor-transduced autologous natural killer T cell therapy · Baylor College of Medicine

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GD2 CAR-NKT cell therapy, covering 2017-06-14 to 2017-06-14. Get the full timeline:

Most recent: Clinical Trial Update: 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA [Phase 1]

See pricing